Contineum Therapeutics Inc.
CTNM | NASDAQ
$13.59
+$0.04 (+0.30%)
Sep 22, 2026, 12:11 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 50M | 50M | 50M | 50M | n/a | n/a |
Cost of Revenue | n/a | 79K | 79K | 79K | 79K | n/a | n/a | n/a | n/a | 42K | 42K | 42K | 42K | n/a | n/a |
Gross Profit | n/a | -79K | -79K | -79K | -79K | n/a | n/a | n/a | n/a | 49.96M | 49.96M | 49.96M | 49.96M | n/a | n/a |
Operating Income | -66.38M | -66.85M | -68.06M | 33.8M | 35.76M | 42.71M | 50.89M | -43.52M | -38.62M | 11.26M | 16.08M | 20.3M | 28.37M | -10.56M | -5.45M |
Interest Income | 8.81M | 8.5M | 8.25M | 8.76M | 9.55M | 9.52M | 8.91M | 8.17M | 7.16M | 5.84M | 4.61M | 3.16M | 1.42M | 743K | 342K |
Pretax Income | -57.56M | -58.44M | -59.98M | -59.39M | -56.86M | -49.83M | -42.26M | -35.62M | -31.73M | 19.58M | 23.17M | 23.59M | 29.96M | -12.34M | -7.51M |
Net Income | -57.56M | -58.44M | -59.98M | -59.39M | -56.86M | -49.83M | -42.26M | -35.46M | -31.45M | 19.13M | 22.72M | 22.98M | 29.23M | -12.34M | -7.51M |
Selling & General & Admin | 18.28M | 17.4M | 16.54M | 16.21M | 15.52M | 14.72M | 12.47M | 10.11M | 8.43M | 6.99M | 6.32M | 6.15M | 4.58M | 2.98M | 1.5M |
Research & Development | 48.1M | 49.38M | 51.44M | 51.7M | 50.44M | 44.36M | 38.42M | 33.42M | 30.19M | 31.75M | 27.6M | 23.55M | 17.05M | 7.59M | 3.95M |
Other Expenses | n/a | n/a | n/a | -101.79M | -101.79M | -101.79M | -101.79M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 66.38M | 66.77M | 67.98M | -33.88M | -35.83M | -42.71M | -50.89M | 43.52M | 38.62M | 38.74M | 33.92M | 29.7M | 21.63M | 10.56M | 5.45M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 116K | 208K | 309K | 309K | 193K | 101K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 48.95M | 66.85M | 68.06M | -33.8M | -35.76M | -42.71M | -50.89M | 43.52M | 38.62M | 38.74M | 33.92M | 29.7M | 21.63M | 10.56M | 5.45M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -161K | -279K | 450K | 450K | 611K | 729K | n/a | n/a |
Shares Outstanding (Basic) | 37.47M | 37.34M | 30.86M | 28.12M | 25.9M | 25.87M | 25.85M | 25.74M | 25.72M | 25.72M | 25.13M | 25.13M | 25.72M | 25.72M | 25.13M |
Shares Outstanding (Diluted) | 37.47M | 37.34M | 30.86M | 28.12M | 25.9M | 25.87M | 25.85M | 25.74M | 25.72M | 25.72M | 25.13M | 25.13M | 25.72M | 25.72M | 25.13M |
EPS (Basic) | -1.73 | -1.95 | -2.18 | -2.25 | -2.20 | -1.93 | -1.64 | -1.13 | -0.98 | 0.99 | 1.13 | 0.88 | 1.13 | -0.49 | -0.30 |
EPS (Diluted) | -1.73 | -1.95 | -2.18 | -2.25 | -2.20 | -1.93 | -1.64 | -1.13 | -0.98 | 0.99 | 1.13 | 0.88 | 1.13 | -0.49 | -0.30 |
EBITDA | -59.58M | -58.12M | -59.66M | -59.07M | -56.57M | -49.56M | -42M | -35.4M | -31.52M | 19.88M | 23.57M | 24.14M | 30.46M | -11.99M | -7.33M |
EBIT | -42.4M | -58.44M | -59.98M | -59.39M | -56.86M | -49.83M | -42.26M | -35.62M | -31.73M | 19.69M | 23.38M | 23.9M | 30.27M | -12.14M | -7.41M |
Depreciation & Amortization | 249K | 328K | 323K | 313K | 294K | 275K | 258K | 220K | 201K | 183K | 195K | 239K | 196K | 154K | 81K |
Add to Watchlist
Select watchlists to add or remove CTNM